HOPA Highlights

The process of clinical trials underwent a dramatic transformation amid the COVID-19 pandemic, according to Heidi D. Finnes, PharmD, BCOP, FHOPA, RPh, Senior Manager, Pharmacy Cancer Research, Mayo Clinic, Rochester, MN.

For more than 40 years, healthcare professionals, public health advocates, and healthcare strategists have been discussing health inequities that consistently and disproportionately affect groups of color in the United States.

The COVID-19 pandemic may have temporarily overshadowed the opioid crisis in the United States, but deaths related to opioid overdose deaths have risen to an all-time high in the past year.

Thrombosis in patients with cancer may be a relatively common complication, but the treatment of venous thromboembolism (VTE) in this patient population is anything but simple.

Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving.

The recent approval of several new HER2-targeted therapies has led to significant advances in the treatment of patients with HER2-positive metastatic breast cancer.

Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease.

According to the American Cancer Society, nearly 35,000 new cases of multiple myeloma will be diagnosed in the United States in 2021, and approximately 12,410 deaths will be attributed to the disease.1 However, with the introduction of several novel therapies, the outcomes for patients with newly diagnosed multiple myeloma have improved significantly over the past decade.

The COVID-19 pandemic caused significant disruptions to virtually all aspects of oncology care.